reviewed april 2026|next review october 2026|88 physicians psi has verified|759 published studies
Cortistatin
Cortistatin is a 17-amino-acid naturally occurring (the body's own) neuropeptide structurally related to somatostatin but with a distinct receptor profile that includes the ghrelin receptor (GHS-R1a) and MrgX2 in addition to all five somatostatin receptors, giving it unique roles in sleep regulation and anti-inflammatory signaling not shared by somatostatin.
Evidence landscape: 759 published studies
Published studies indexed under this compound. The cortistatin literature is smaller than the somatostatin literature but growing as the distinct biology becomes better characterized.
- 44 Human
- 138 Animal
- 18 Reviews
- 559 Other research
Not FDA-approved. No cortistatin-based therapeutic is in clinical development. Research is entirely in animal models (preclinical).
Not commercially available as a therapeutic. Naturally occurring (the body's own) neuropeptide produced primarily in the cerebral cortex. Available as a research compound from specialty suppliers.
Shares 11 of 17 residues with somatostatin but binds additional receptors (ghrelin receptor GHS-R1a and MrgX2) that somatostatin does not. This expanded receptor profile gives cortistatin biological activities distinct from somatostatin, particularly in sleep regulation and cortical function.
PSI Assessment
Cortistatin shares structural similarity with somatostatin but does things somatostatin does not. It promotes deep, slow-wave sleep through direct cortical neuron inhibition. It has potent anti-inflammatory effects that protected mice from lethal sepsis. And it binds the ghrelin receptor, a target associated with appetite and growth hormone release. The expanded receptor profile makes cortistatin biologically unique, even though no human therapeutic data exists. The sleep-promoting effects are the most distinctive angle because few naturally occurring peptides have been shown to specifically enhance slow-wave activity.
Structurally related to somatostatin but with a distinct receptor profile. Promotes slow-wave sleep. Potent anti-inflammatory effects in animal sepsis models. No human therapeutic data.
The mechanism involves activation of all five somatostatin receptors (SST1-5) plus the ghrelin receptor (GHS-R1a) and MrgX2 receptor. In the cerebral cortex, cortistatin hyperpolarizes neurons to promote slow-wave sleep. In immune cells, it suppresses NF-kB signaling and reduces pro-inflammatory cytokine production (TNF-alpha, IL-6), while increasing the anti-inflammatory cytokine IL-10. The ghrelin receptor binding distinguishes cortistatin from somatostatin at the molecular level.
What the evidence supports
Cortistatin promotes slow-wave sleep through cortical neuron hyperpolarization in animal models (animal research). Potent anti-inflammatory effects through NF-kB suppression are documented in multiple autoimmune and inflammatory animal models. The peptide binds all five somatostatin receptors plus the ghrelin receptor (GHS-R1a) and MrgX2, giving it a receptor profile distinct from somatostatin.
What is not yet established
Any human clinical data for cortistatin as a therapeutic. Whether the sleep-promoting or anti-inflammatory effects translate to humans. Whether stable analogs can overcome the short half-life limitation for clinical development.
Research Evidence
The findings below cover the sleep, anti-inflammatory, and neuroendocrine effects characterized in animal models (animal research).
Evidence by condition
Evidence dimensions across cortistatin research areas. Sleep regulation and anti-inflammatory effects have the most consistent animal model data. Neuroendocrine modulation is less characterized.
| Condition | Mechanism | Animal evidence | Human evidence | Replication |
|---|---|---|---|---|
| Sleep Regulation | ||||
| Inflammatory Bowel Disease | ||||
| Neuroendocrine Modulation | ||||
| Sepsis |
Cortistatin enhances slow-wave sleep in animal models through direct cortical neuron hyperpolarization. The sleep-promoting effect is distinct from somatostatin, which does not produce the same cortical sleep patterns despite sharing receptor affinity.
The original discovery by de Lecea et al. identified cortistatin in the cerebral cortex and immediately recognized its sleep-modulating properties. The specificity for slow-wave sleep, the most restorative sleep phase, distinguishes cortistatin from other sleep-related peptides.
Cortistatin administration protected mice from lethal endotoxemia (sepsis) by suppressing the inflammatory cytokine storm. It reduced TNF-alpha, IL-6, and other pro-inflammatory mediators while increasing anti-inflammatory IL-10.
The anti-inflammatory potency in this model was notable. Cortistatin also showed therapeutic effects in models of inflammatory bowel disease and rheumatoid arthritis, suggesting broad anti-inflammatory activity rather than a model-specific effect.
Cortistatin binds the ghrelin receptor (GHS-R1a), a receptor associated with appetite regulation and growth hormone release. This binding is not shared by somatostatin despite the structural similarity between the two peptides.
The ghrelin receptor binding may explain some of cortistatin's neuroendocrine effects that differ from somatostatin. Whether this interaction has therapeutic relevance is not established.
44 Human|138 Animal|18 Reviews
View all 759 indexed studiesHow Cortistatin Works
Cortistatin is produced by the brain's outer layer (cortex) and helps regulate deep sleep. It acts like a calming signal that reduces neuronal firing and promotes the slow-wave activity associated with restorative sleep. It also dampens inflammation throughout the body, having protected mice from fatal sepsis by suppressing the inflammatory cascade.
Cortistatin is produced by the brain's outer layer (cortex) and helps regulate deep sleep. It acts like a calming signal that reduces neuronal firing and promotes the slow-wave activity associated with restorative sleep. It also dampens inflammation in the brain.
For a more detailed view of the biology, here is what researchers have observed at the molecular level.
Cortistatin is a 17-amino-acid neuropeptide (sharing 11 residues with somatostatin-14) that binds all five somatostatin receptors (SST1-5) plus the ghrelin receptor (GHS-R1a) and MrgX2 receptor. In the cerebral cortex, it hyperpolarizes neurons via enhanced potassium conductance, promoting slow-wave sleep oscillations. Anti-inflammatory effects are mediated by NF-kB suppression and cytokine modulation (reduced TNF-alpha, IL-6, IL-12; increased IL-10). The short half-life in circulation limits therapeutic utility of the native peptide.
What is Cortistatin being studied for?
Researchers are studying Cortistatin across several health conditions. Each condition below is labeled with the strength of evidence that exists for that specific use, not for Cortistatin overall. This means a compound can have human studies for one condition but only animal data for another.
Sleep Regulation
·Animal StudiesCortistatin promotes slow-wave sleep in animal models (animal research) through cortical neuron hyperpolarization. The sleep-promoting effect is distinct from somatostatin.
Limitations: No human sleep studies. Whether cortistatin-based interventions could improve sleep quality in humans is entirely theoretical.
Inflammatory Bowel Disease
·Animal StudiesCortistatin has anti-inflammatory effects in animal models (animal research) of colitis and inflammatory bowel disease through NF-kB suppression and cytokine modulation.
Limitations: Human data is limited to observational and mechanistic studies. Whether the anti-inflammatory effects translate to human IBD treatment is untested.
Neuroendocrine Modulation
·Animal StudiesCortistatin modulates growth hormone secretion and interacts with the ghrelin receptor system. The expanded receptor profile gives it neuroendocrine effects not shared by somatostatin.
Limitations: Neuroendocrine effects characterized in animal models only. The clinical significance of cortistatin's ghrelin receptor binding is not established.
Sepsis
·PreclinicalCortistatin protected mice from lethal endotoxemia by suppressing the inflammatory cytokine storm. The effect was potent but demonstrated only in a single animal model.
Limitations: Sepsis protection demonstrated in one laboratory model. Human data is limited to expression and receptor characterization studies. The gap between murine sepsis models and human sepsis biology is substantial.
Safety and Regulatory Status
FDA Status: Not FDA-approved. No cortistatin-based therapeutic is in development. Research is entirely in animal models.
Availability: Not commercially available as a therapeutic. Available as a research compound from specialty suppliers.
Class context: Naturally occurring (the body's own) neuropeptide. No human administration data exists. The short half-life of the native peptide limits systemic exposure, which is theoretically favorable from a safety perspective.
Cortistatin is naturally occurring (the body's own) with no safety concerns from normal physiology. No human therapeutic administration studies have been conducted, so a formal human safety profile does not exist. The structural similarity to somatostatin suggests the receptor-mediated effects would be generally well tolerated.
Peptide Structure
Technical molecular data for researchers and clinicians.
Questions and Comparisons
Questions the evidence raises for a Cortistatin discussion.
Comparison and Related Research
Cortistatin is most naturally compared with somatostatin, from which it diverges despite structural similarity.
Related compounds
Frequently Asked Questions
References
Each citation links to the original study on PubMed, the U.S. National Library of Medicine database.
- 1.The original discovery of cortistatin as a neuropeptide expressed in the cerebral cortex and hippocampus. Researchers found that cortistatin enhanced slow-wave sleep in rats and reduced neuronal excitability, establishing its dual role in sleep regulation and neural activity modulation. Despite structural similarity to somatostatin, cortistatin showed distinct biological functions.de Lecea L et al., 1996 in Nature. View on PubMed
- 2.Demonstrated that cortistatin administration protected mice from lethal sepsis by suppressing the inflammatory cytokine storm. The peptide reduced TNF-alpha, IL-6, and other pro-inflammatory mediators while increasing the anti-inflammatory cytokine IL-10, revealing cortistatin as a potent endogenous regulator of the immune response.Gonzalez-Rey E et al., 2003 in Ann N Y Acad Sci. View on PubMed
- 3.Mapped the expression of cortistatin across human tissues including immune organs, brain, stomach, and pancreas. The study found cortistatin mRNA in human lymphocytes and monocytes, supporting a role for this peptide in immune system regulation that is distinct from somatostatin's primarily endocrine functions.Dalm VA et al., 2004 in Mol Cell Endocrinol. View on PubMed
- 4.Showed that cortistatin treatment reduced intestinal inflammation in mouse models of colitis. The peptide decreased inflammatory cell infiltration, reduced tissue damage scores, and suppressed pro-inflammatory cytokine production in the colon. The results suggested cortistatin may have therapeutic applications in inflammatory bowel disease.Gonzalez-Rey E et al., 2006 in Gastroenterology. View on PubMed
- 5.Investigated how cortistatin modulates macrophage behavior during intestinal inflammation. The study found that cortistatin shifted macrophages toward an anti-inflammatory phenotype, reducing their production of tissue-damaging molecules while maintaining their ability to clear bacteria. This provided a mechanistic explanation for the anti-inflammatory effects observed in colitis models.Souza-Moreira L et al., 2014 in J Leukoc Biol. View on PubMed
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.